| 產(chǎn)品編號 | BIO0976SM |
| 英文名稱 | Anti-BCMA & CD3 Reference Antibody (Linvoseltamab Biosimilar) |
| 別 名 | TNFRSF17 / BCMA / CD269 & CD3; Linvoseltamab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145.78kDa |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Linvoseltamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Linvoseltamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.678 nM.
Linvoseltamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to huBCMA-HEK293 cells, and the EC50 was 2.486 nM.
Linvoseltamab bound to Jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to Jurket cells, and the EC50 was 11.160 nM.
Linvoseltamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Linvoseltamab bound to huBCMA-ECD-His, and the EC50 was 0.096 nM.
The purity of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 97.71%, determined by SEC-HPLC.
Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 145.95 kDa.
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
